Corinfar Retard tablets 20mg, No. 30
Expiration Date: 05/2027
Russian Pharmacy name:
Коринфар Ретард таблетки 20мг, №30
chronic stable angina (exertional angina);
vasospastic angina (Prinzmetal's angina, variant angina);
arterial hypertension.
Inside, after meals, without chewing and drinking plenty of fluids. Simultaneous food intake delays, but does not reduce the absorption of the active substance from the gastrointestinal tract.
The dose of the drug is selected by the doctor individually in accordance with the severity of the disease and the patient's sensitivity to the drug. For patients with concomitant severe cerebrovascular diseases and in elderly patients, the dose should be reduced.
Chronic stable and vasospastic angina: 20 mg (1 table) 2 times a day. With insufficiently pronounced clinical effect, the dose of the drug is gradually increased to 40 mg (table 2) 2 times a day. The maximum daily dose is 80 mg (table 4).
Essential hypertension: 20 mg (1 table) 2 times a day. With insufficiently pronounced clinical effect, the dose of the drug is gradually increased to 40 mg (table 2) 2 times a day. The maximum daily dose is 80 mg (table 4).
If the drug is administered twice a day, the interval between doses should be on average 12 hours. The minimum interval between doses of the drug is at least 4 hours.
The duration of the course of treatment is determined by the attending physician.
In cases where the drug is taken in large doses and / or for a long time, treatment should be stopped gradually in order to avoid withdrawal syndrome.
| Sustained-release film-coated tablets | 1 tab. |
| active substance: | |
| nifedipine | 20 mg |
| excipients: lactose monohydrate - 31.6 mg; potato starch - 31.4 mg; MCC - 31 mg; povidone K25 - 5.4 mg; magnesium stearate - 0.6 mg | |
| film shell: hypromellose - 5.188 mg; macrogol 6000 - 0.861 mg; macrogol 35000 - 0.393 mg; dye quinoline yellow (E104) - 0.143 mg; titanium dioxide (E171) - 1.377 mg; talc - 1.038 mg |
hypersensitivity to nifedipine and other derivatives of 1,4-dihydropyridine, or other components of the drug;
arterial hypotension (SBP below 90 mm Hg);
cardiogenic shock, collapse;
severe aortic stenosis;
chronic heart failure in the stage of decompensation;
unstable angina;
acute myocardial infarction (first 4 weeks);
pregnancy (I trimester);
lactation period;
combined use with rifampicin.
With care: severe mitral stenosis; hypertrophic obstructive cardiomyopathy; severe bradycardia or tachycardia; sick sinus syndrome; malignant arterial hypertension; hypovolemia; severe disorders of cerebral circulation; myocardial infarction with left ventricular failure; obstruction of the gastrointestinal tract; renal and hepatic impairment; hemodialysis; pregnancy (II and III trimesters); age under 18; simultaneous reception of beta-blockers, digoxin.